Publications by authors named "Qinming Zeng"
Front Pharmacol
July 2023
Article Synopsis
- The study assessed the comparative effectiveness of 6 HIF-PHIs and 3 ESAs for treating anemia in renal patients on dialysis, based on data from 25 randomized controlled trials involving over 17,000 participants.
- No significant differences were found between HIF-PHIs and ESAs in achieving target hemoglobin (Hb) levels, although roxadustat showed a lower risk of requiring red blood cell transfusions compared to rhEPO.
- HIF-PHIs demonstrated advantages in reducing hepcidin levels and improving iron status, but some (roxadustat and vadadustat) had higher discontinuation rates compared to ESAs.
